BEAM-302 (for Beam Therapeutics)
Alpha-1 Antitrypsin Deficiency (AATD)
Phase 1/2Active
Key Facts
Indication
Alpha-1 Antitrypsin Deficiency (AATD)
Phase
Phase 1/2
Status
Active
Company
About Richmond Pharmacology
Richmond Pharmacology is a specialized, founder-led Contract Research Organization (CRO) with a strong niche in early-phase clinical trials, particularly for complex modalities like gene editing and RNAi therapies. It differentiates itself through operational speed, aiming to move assets from FIH to POC in under a year, and claims global leadership in conducting in-vivo gene-editing clinical trials. The company serves a mix of top pharmaceutical firms and biotechs, leveraging its expertise in cardiovascular diseases, rare diseases, and innovative therapeutic platforms to accelerate drug development.
View full company profileTherapeutic Areas
Other Alpha-1 Antitrypsin Deficiency (AATD) Drugs
| Drug | Company | Phase |
|---|---|---|
| Unnamed AATD Program | AlveoGene | Pre-clinical |
| NB-101 | Nerai Biosciences | Pre-clinical |
| Undisclosed | GondolaBio | IND Enabling |
| TSRA-196 | Tessera Therapeutics | Phase 1 |
| KB408 | Krystal Biotech | Preclinical |
| Alpha-1 Antitrypsin (AAT) | Grifols | Marketed |
| BEAM-302 | Beam Therapeutics | Phase 1/2 |
| GalNAc Program | Korro Bio | Preclinical |